Ingen Technologies Inc. (OTC: IGNT) said that shareholders approved at a recent conference the acceptance of an option to take the company to the OTC.
More recently, the company is also strongly considering a listing on the American Stock Exchange (AMEX) pursuant to discussions and the evaluation of a memorandum of understanding with Benchmark Advisory Partners.
“The company has resolved the majority of its debt issues, as well as being in the process of removing the DTCC ´CHILL´ on its stock,” said Gary Tilden, chairman. “Both of our subsidiaries are in profitable market sectors with growing industry economics, where increased revenues are beginning to become apparent. This growth should result in stronger shareholder value for our current and future shareholders. The move to the OTC or AMEX will only enhance the progress already being made.”
Ingen Technologies was established in 1999 to research and develop home healthcare products for the growing respiratory market. The global medical device industry is growing rapidly, with a value expected to hit $228 billion by 2015, up from $164 billion in the year 2010, marking annual growth of nearly 7%. COPD (chronic obstructive pulmonary disease) includes chronic bronchitis, emphysema, and asthmatic bronchitis, all of which obstruct airflow from the lungs. It is a leading cause of death, illness, and disability in the United States, and other large countries. The company´s website is at ingen-tech.com.